Literature DB >> 26169611

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Giorgio Scagliotti1, Joachim von Pawel2, Silvia Novello2, Rodryg Ramlau2, Adolfo Favaretto2, Fabrice Barlesi2, Wallace Akerley2, Sergey Orlov2, Armando Santoro2, David Spigel2, Vera Hirsh2, Frances A Shepherd2, Lecia V Sequist2, Alan Sandler2, Jeffrey S Ross2, Qiang Wang2, Reinhard von Roemeling2, Dale Shuster2, Brian Schwartz2.   

Abstract

PURPOSE: Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased anticancer activity in preclinical and early clinical studies when combined with erlotinib. Our study aimed to confirm efficacy and safety of the combination in previously treated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC previously treated with one to two systemic regimens, including a platinum doublet, were randomly assigned at a 1:1 ratio to receive erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily (E + T) or erlotinib plus placebo (E + P) until disease progression. Tumor specimens were evaluated for EGFR and KRAS mutations, MET expression, and MET gene amplification. The primary end point was overall survival (OS). Secondary and exploratory objectives included progression-free survival (PFS), OS in molecular subgroups, and safety.
RESULTS: The study enrolled 1,048 patients and was discontinued for futility at the interim analysis. OS did not improve with E + T versus E + P (median OS, 8.5 v 7.8 months, respectively; hazard ratio [HR], 0.98; 95% CI, 0.84 to 1.15; P = .81), even though PFS increased (median PFS, 3.6 v 1.9 months; HR, 0.74; 95% CI, 0.62 to 0.89; P < .001). Exploratory subgroup analyses suggested OS improvement in patients with high MET expression (HR, 0.70; 95% CI, 0.49 to 1.01). Most common adverse events occurring with E + T versus E + P were rash (33.1% v 37.3%, respectively), diarrhea (34.6% v 41.0%), asthenia or fatigue (43.5% v 38.1%), and neutropenia (grade 3 to 4; 8.5% v 0.8%).
CONCLUSION: E + T was well tolerated and increased PFS but did not improve OS in the overall nonsquamous NSCLC population.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26169611     DOI: 10.1200/JCO.2014.60.7317

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  118 in total

1.  MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Authors:  Thanyanan Reungwetwattana; Sai-Hong Ignatius Ou
Journal:  Transl Lung Cancer Res       Date:  2015-12

Review 2.  Drug Resistance to EGFR Inhibitors in Lung Cancer.

Authors:  Osamu Tetsu; Matthew J Hangauer; Janyaporn Phuchareon; David W Eisele; Frank McCormick
Journal:  Chemotherapy       Date:  2016-02-25       Impact factor: 2.544

Review 3.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

4.  Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.

Authors:  Yanjun Xu; Yun Fan
Journal:  Cancer Biol Ther       Date:  2018-11-13       Impact factor: 4.742

5.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

6.  Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.

Authors:  Masaya Tachibana; Kyriakos P Papadopoulos; John H Strickler; Igor Puzanov; Roohi Gajee; Yibin Wang; Hamim Zahir
Journal:  Br J Clin Pharmacol       Date:  2017-10-29       Impact factor: 4.335

Review 7.  The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.

Authors:  Hwajeong Lee; Jeffrey S Ross
Journal:  Therap Adv Gastroenterol       Date:  2017-03-28       Impact factor: 4.409

8.  Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Authors:  Magda Bahcall; Taebo Sim; Cloud P Paweletz; Jyoti D Patel; Ryan S Alden; Yanan Kuang; Adrian G Sacher; Nam Doo Kim; Christine A Lydon; Mark M Awad; Michael T Jaklitsch; Lynette M Sholl; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

9.  Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer.

Authors:  Nagio Takigawa; Nobuaki Ochi; Hiromichi Yamane
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 10.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.